2023年12月1～3日，欧洲肿瘤内科学会亚洲峰会（ESMO ASIA 2023）在狮城新加坡顺利召开。会议汇聚肿瘤领域众多国际权威专家学者，围绕各种前沿学术进展进行交流讨论。在非小细胞肺癌（NSCLC）领域，抗体偶联药物（ADC）的进展日新月异。本期《肿瘤瞭望》有幸邀请到华中科技大学同济医学院附属协和医院董晓荣教授系统阐述了在NSCLC治疗中ADC的发展现状以及最新进展。
Video Player is loading.
Current Time 0:00
Duration 0:00
Remaining Time -0:00
This is a modal window.
The media could not be loaded, either because the server or network failed or because the format is not supported.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
04
肿瘤瞭望：您对未来ADC在NSCLC的应用有哪些期待？
董晓荣教授：在本次ESMO Asia的大会报道中，我们看到了关于靶向HER2、Trop-2的ADC的最新进展，它们为NSCLC患者进一步的精准治疗带来更多的选择和期待。
首先，我希望随着更多临床数据的积累和研究的深入，ADC药物能够得到更广泛的认可，为NSCLC患者带来更多标准化治疗选择。希望越来越多的ADC药物能够加快研究进展，公布更多数据，促进NSCLC精准治疗的发展。
其次，期望ADC药物能够进一步强化NSCLC患者的精准化、个体化治疗。期望在精准治疗指导下，ADC药物能够带来更好的疗效和更少的不良反应。
最后，期待ADC药物能够与其他治疗方式进行联合应用，如化疗、放疗、免疫治疗等。通过联合应用，可以更好地发挥各种治疗方式的优势，助力NSCLC治疗水平的提升。
总之，我对ADC药物在NSCLC领域的应用与发展充满期待。我相信，随着研究的深入和技术的进步，ADC药物将会为NSCLC患者带来更好的治疗选择和更高的生存希望。
参考文献
[1]van der Velden VH，Boeckx N，Jedema I，et al.High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin(Mylotarg)treatment in acute myeloid leukemia patients.Leukemia.2004;18(5):983-988.doi:10.1038/sj.leu.2403350
[2]Hunter FW，Barker HR，Lipert B，et al.Mechanisms of resistance to trastuzumab emtansine(T-DM1)in HER2-positive breast cancer.Br J Cancer.2020;122(5):603-612.doi:10.1038/s41416-019-0635-y
[3]Ogitani Y，Aida T，Hagihara K，et al.DS-8201a，A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor，Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.Clin Cancer Res.2016;22(20):5097-5108.doi:10.1158/1078-0432.CCR-15-2822
[4]Wen S，Dai L，Wang L，et al.Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.Oncologist.2019 Nov;24(11):e1070-e1081.
[5]Mazières J，Barlesi F，Filleron T，et al.Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs:results from the European EUHER2 cohort.Ann Oncol.2016;27(2):281-286.
[6]Li BT，Smit EF，Yasushi Goto Y，et al.Phase 2 Trial of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small Cell Lung Cancer:Updated Analyses From DESTINY-Lung01.2022ESMO.976P.
[7]Koichi Goto，Yasushi Goto，et al.510MO-Trastuzumab deruxtecan(T-DXd)in Asian patients(Pts)with human epidermal growth factor receptor 2(HER2;ERBB2)-mutant(HER2m)metastatic non-small cell lung cancer(mNSCLC):Subgroup analysis of DESTINY–Lung02(DL-02).2023 ESMO Asia 510MO.
[8]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南2023.北京:人民卫生出版社，2023.4.
[9]Ren S，Wang J，Ying J，et al.Consensus for HER2 alterations testing in non-small-cell lung cancer[published correction appears in ESMO Open.2022 Jun;7(3):100482].ESMO Open.2022;7(1):100395.
[10]Inamura K，Yokouchi Y，Kobayashi M，et al.Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes.Oncotarget.2017 Apr 25;8(17):28725-28735.
[11]Mito R，Matsubara E，Komohara Y，et al.Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation.Pathol Int.2020 May;70(5):287-294.
[12]Heist RS，Guarino MJ，Masters G，et al.Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate，Sacituzumab Govitecan.J Clin Oncol.2017 Aug 20;35(24):2790-2797.
[13]Fang WF，Cheng Y，Chen ZD，et al.SKB264(TROP2-ADC)for the treatment of patients with advanced NSCLC:Efficacy and safety data from a phase 2 study.2023 ASCO.9114.
[14]Myung-Ju Ahn，Aaron E.Lisberg，et al.509MO-Datopotamab deruxtecan(Dato-DXd)vs docetaxel in previously treated advanced/metastatic(adv/met)non-small cell lung cancer(NSCLC):Results of the randomized phase III study TROPION-Lung01.2023 ESMO Asia 509MO.
[15]Satoru Kitazono，Luis Paz-Ares et al.518MO-TROPION-Lung05:Datopotamab deruxtecan(Dato-DXd)in previously treated non-small cell lung cancer(NSCLC)with actionable genomic alterations(AGAs).2023 ESMO Asia 518MO.
[16]Myung-Ju Ahn，Byoung Chul Cho et al.552P-TROPION-Lung05:Datopotamab deruxtecan(Dato-DXd)in Asian patients(pts)with previously treated non-small cell lung cancer(NSCLC)with actionable genomic alterations(AGAs).2023 ESMO Asia 552P.
董晓荣教授
华中科技大学同济医学院附属协和医院
三级教授主任医师博士生导师
华中科技大学协和医院肿瘤科/教研室副主任
华中科技大学协和医院肿瘤中心胸部肿瘤科主任
中国临床肿瘤学会理事
中国医药教育协会肺部肿瘤专委会副主任委员
中国抗癌协会肺癌专家委员会常委
中国临床肿瘤学会免疫专家委员会常委
中国临床肿瘤学会血管靶向治疗专家委员会常委
中国临床肿瘤学会患者教育专家委员会常委
中国临床肿瘤学会非小细胞肺癌专家委员会委员
湖北省抗癌协会肿瘤免疫治疗专委员会主任委员
湖北省抗癌协会肿瘤内科治疗专委员会副主任委员
京公网安备 11010502033352号